Evidence-Based Systematic Literature Review of Hemoglobin/Hematocrit and All-Cause Mortality in Dialysis Patients
To access this article, please choose from the options below
N.V. and L.A. were employed by Amgen Inc at the time the work started, and both subsequently left the company. Research support therefore was received in part as salary, but no other funding of this project has been received from Amgen subsequently. The work continued at University of California at Los Angeles (L.A.) and Rollins School of Public Health, Emory University (N.V.).
Originally published online as doi:10.1053/j.ajkd.2005.09.007 on November 14, 2005.
PII: S0272-6386(05)01350-8
doi:10.1053/j.ajkd.2005.09.007
© 2005 National Kidney Foundation, Inc. Published by Elsevier Inc All rights reserved.
Refers to article:
- Target Hemoglobin Level for EPO Therapy in CKD
